Encysive agrees to work with FDA on Thelin study

HOUSTON Encysive Pharmaceuticals is planning on moving its hypertension drug candidate Thelin into a late-stage study, according to the Associated Press.

The drug, indicated for hypertension, has been repeatedly denied approval by the Food and Drug Administration. The agency has sent three letters of request for more information from the company since they first applied for approval in 2005. The FDA wants the company to conduct a new study before it would be considered for approval.

The company has said it will work with the FDA to finish a protocol for the Phase III clinical trial.

Poll

Poll

SPECIAL REPORTS

Are we in the midst of a beauty revolution? Perhaps. It is no secret that the ever-changing beauty category is all about trends, but one could argue that we are embarking on an especially interesting time in beauty as technology is changing the way consumers shop and new innovations strive to break through the noise.

In this beauty report, Drug Store News takes a deeper dive into some of the leading trends that are reshaping beauty.more ...

IN THIS ISSUE

In this issue, DSN examines PricewaterhouseCoopers' "Top Health Industry Issues for 2015;" takes you on a tour of Murad, shares beauty trends and insights and delves into location-based technology and how it is revolutionizing health, retail.Click here to view the issue.